The Accelerating Medicines Partnership (AMP)
Heart Failure (HF) is an innovative new project that
uses next-generation phenomics to define heart failure
subtypes and treatment targets
The Accelerating Medicines
Partnership® (AMP®) Heart
Failure (HF)
Read MoreAMP-HF

Study Sites

The AMP HF Study consists of a data translation center and 7 clinical research centers.

Learn More

If you or a family member is interested in the HeartShare study, or if you or a family member have been invited to participate, you may have questions.

Users Users

Learn More

Meet the HeartShare Community: nearly 5,000 people have joined since HeartShare began in 2023. Contributions from our participants will help us make discoveries to help improve heart health!

Find Information

Understand what’s involved in joining HeartShare, including who can participate and what participants are expected to do.

Chat Chat

Contact us

If you still have questions, you can contact the Data Translation Center at Northwestern or one of the clinical centers. Contact information for each location is listed on our contact page.

Study Design

The AMP HF Study is an innovative multi-center study of HFpEF, funded by NHLBI to define HFpEF subtypes and treatment targets.

HeartShare is comprised of retrospective and prospective components.

The HeartShare Retrospective study will aggregate and harmonize data from previously completed cohort studies and trials. The phenotype data will be combined with an image repository and additional omics assays.

The HeartShare Deep Phenotyping Study is composed of 2 prospective, multicenter, longitudinal components: (1) the HeartShare Registry and (2) the HeartShare Deep Phenotyping Cohort study involving up to 10,000 and 2,000 participants, respectively, enrolled from at least 7 HeartShare Clinical Centers.

Retrospective and Prospective Data

Multiple data types will be harmonized.

Existing data sets from cohort studies and trials, including images and omics analyses, will be aggregated and harmonized to establish the retrospective data.

Details of what cohort studies and trials will be in the retrospective data will be available soon.

Prospective data is being generated from the registry and deep phenotyping study cohorts.  Both cohorts have baseline and longitudinal data.

Get Involved

Contribute data or apply for access to the data or establish an ancillary study in AMP HF

Helpful links for details and information about how you can get involved or collaborate:

Data Sharing / BioData Catalyst

Research Skills Program

Ancillary Studies and Publications

For more information, contact us.